| MDL | - |
|---|---|
| Molecular Weight | 244.12 |
| Molecular Formula | C10H11Cl2N3 |
| SMILES | ClC1=C(Cl)C=C(N2C[C@]3([H])CN[C@]3([H])C2)C=N1 |
Sofiniclin is more potent than ABT-089 at both receptor subtypes, with K i values of 1.9 nM for 125 I-α-conotoxinMII binding and of 1.3 nM for 125 I-epibatidine binding [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs compared to vehicle monkey [1] . Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00548925 | AbbVie (prior sponsor, Abbott)|AbbVie |
Diabetic Neuropathic Pain
|
November 2007 | Phase 2 |
| NCT00429091 | Abbott |
Attention-Deficit+Hyperactivity Disorder|ADHD
|
January 2007 | Phase 2 |
| NCT00507936 | AbbVie (prior sponsor, Abbott)|AbbVie |
Diabetic Neuralgia|Diabetic Neuropathies|Diabetic Neuropathy, Painful|Diabetic Polyneuropathy|Neuralgia, Diabetic
|
August 2007 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 35.71 mg/mL ( 146.28 mM ; ultrasonic and warming and heat to 60°C)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.0963 mL | 20.4817 mL | 40.9635 mL |
| 5 mM | 0.8193 mL | 4.0963 mL | 8.1927 mL |
| 10 mM | 0.4096 mL | 2.0482 mL | 4.0963 mL |